Can kids with eczema take less medicine? new study aims to find out

NCT ID NCT06116526

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether children aged 1 to 17 with well-controlled atopic dermatitis (eczema) can safely reduce their dose or stop taking dupilumab (Dupixent) without their skin condition getting worse. About 30 children who have been on dupilumab for at least a year and have had good control for the last 6 months will be randomly assigned to continue the standard dose, take a lower dose, or stop the drug. The goal is to see if de-escalation is possible while keeping eczema under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab (Dupixent)
What this could lead to: If successful, this could show that some children with well-controlled eczema can safely take less medication or stop it altogether, reducing treatment burden and side effects.
What could go wrong: This is a small pilot study with only 30 children, so results may not apply to everyone. Some children may need to restart or increase their dose if eczema flares up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Johns Hopkins Univerisity
RECRUITING

Baltimore, Maryland, 21210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.